Analyst Reports
Monday, 06 February 2012
Nomura Quick Note: "MAA review should complete by start 4QCY12"
CUV announced that it has submitted a marketing authorisation application (MAA) for…
Thursday, 05 January 2012
Edison QuickView: Positive in Phase III
Positive results in the second Phase III study of Clinuvel’s Scenesse (afamelanotide),…
Tuesday, 20 December 2011
Nomura Quick Note: "Positive result from pivotal EU Phase III study"
The latest analyst coverage of Clinuvel from Nomura has just been…
Thursday, 03 November 2011
Nomura Update "CUV's statistically significant EPP results"
Clinuvel demonstrates positive treatment effect of afamelanotide in US Phase II study…
Friday, 02 September 2011
Nomura Update "Vitiligo - addressing a large unmet need"
Considerable upside from potentially successful NSV trials
Friday, 26 August 2011
Nomura Update "FY11 - looking to enter the Vitiligo market"
We believe the Vitiligo market is currently underserved
